Furthermore, ABBV-399 monotherapy was evaluated in Phase I clinical trial, being administered intravenously every two weeks (1.6-2.2 mg/kg) or every three weeks (0.15-3.3 mg/kg), with a dose-expansion phase focusing on patients with c-MET+ NSCLC or MET amplification/exon 14 skipping mutations (ClinicalTrials.gov identifier: NCT02099058). The gene discussed is MET; the disease is non-small cell lung carcinoma.